Clinical Trials on Charcot-Marie-Tooth Disease Type 2L (Diagnosis)

Total 1619 results

Wei Jiang
Wuzhou Red Cross Hospital; Laibin People's Hospital; Lingshan people's Hospital; Nanxishan Hospital of Guangxi Zhuang Autonomous Region and other collaborators

Recruiting

Induction Chemotherapy Followed by IMRT or Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Fujian Cancer Hospital

Not yet recruiting

Elective Level Ib Irradiation in Nasopharyngeal Carcinoma Patients Based on the International Guidelines

Nasopharyngeal Carcinoma
National Cancer Centre, Singapore

Recruiting

Treatment Individualisation by EBV Stratification in Nasopharyngeal Carcinoma: a Prospective Observational Study

Nasopharyngeal Carcinoma

Singapore
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Sun Yat-sen University
Chongqing University Cancer Hospital; Xiangya Hospital of Central South University and other collaborators

Recruiting

Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Sun Yat-sen University
The First Hospital of Nanchang

Not yet recruiting

PD-1 Blockade and Bevacizumab Replace Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Guangxi Medical University

Not yet recruiting

Hearing Toxicity of Nasopharyngeal Carcinoma After Chemoradiotherapy

Nasopharyngeal Carcinoma
Jun-Lin Yi, MD

Recruiting

Optimization of Cervical Nodal CTV for Early and Medium Stage NPC

Nasopharyngeal Carcinoma

China
Zhejiang Cancer Hospital
Ningbo Medical Center Lihuili Hospital; Renmin Hospital of Wuhan University; First... and other collaborators

Recruiting

Immune Score Based Radiomics in Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Wei Jiang
Wuzhou Red Cross Hospital; Guangxi Nanxishan Hospital; Laibin People's Hospital; Lingshan people's Hospital

Recruiting

Camrelizumab for the Treatment of Locally Advanced Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Sun Yat-sen University
Guangdong Provincial People's Hospital; Affiliated Cancer Hospital & Institute... and other collaborators

Recruiting

Camrelizumab Plus Stereotactic Body Radiotherapy vs Camrelizumab Alone For Oligometastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Not yet recruiting

Paclitaxel (Albumin-bound) Combined With Radiotherapy for the Treatment of Early Stage Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma
Sun Yat-sen University

Not yet recruiting

Umbrella Biomarker-Guided Therapy in NPC

Nasopharyngeal Carcinoma

China
Chinese University of Hong Kong

Recruiting

Magnifying NBI for Occult NPC

Nasopharyngeal Carcinoma

Hong Kong
Jiangxi Provincial Cancer Hospital

Recruiting

Adding PD-1 Inhibitor to Neoadjuvant and Adjuvant for NPC

Nasopharyngeal Carcinoma

China
Fifth Affiliated Hospital, Sun Yat-Sen University

Recruiting

Gemcitabine-based Induction Chemotherapy Combined With Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Fudan University
Nanfang Hospital of Southern Medical University; Ningbo Medical Center Lihuili... and other collaborators

Recruiting

Comparing Chemotherapy With/Without Toripalimab For Primary Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Xinqiao Hospital of Chongqing
TCRCure Biopharma Ltd.

Recruiting

EBV Specific Cytokine Secreting TCR-T Cells in the Treatment of EBV-Positive Metastatic/Refractory Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
First People's Hospital of Foshan

Not yet recruiting

Toripalimab Combined With Chemoradiotherapy in Patients With Locoregionally-advanced Nasopharyngeal Carcinoma

Nasopharyngeal Neoplasms
Affiliated Cancer Hospital & Institute of Guangzhou...

Recruiting

Nedaplatin Versus Cisplatin in Treatment for Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Fujian Cancer Hospital
Zhejiang Cancer Hospital; Jiangxi Provincial Cancer Hospital

Not yet recruiting

Triprilimab(JS001) and Chemotherapy Combined With Local Treatment for Multiple Metastatic NPC

Nasopharyngeal Carcinoma

China
West China Hospital

Not yet recruiting

Induction Chemotherapy Plus Radiotherapy Alone in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Fujian Cancer Hospital
Zhejiang Cancer Hospital; Jiangxi Provincial Cancer Hospital

Not yet recruiting

Sufficient Chemotherapy Combine With Maintenance Chemotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Jiangsu Cancer Institute & Hospital

Not yet recruiting

Endostar Combined With Induction Chemotherapy and Concurrent Chemoradiotherapy for Locoregional Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma
Chaosu Hu
Zhejiang Cancer Hospital; Fujian Cancer Hospital; Affiliated Hospital of Jiangnan... and other collaborators

Recruiting

Sequential or Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced NPC

Nasopharyngeal Carcinoma

China
Sun Yat-sen University
Guilin Medical University, China; First People's Hospital of Foshan

Recruiting

Prospective Study for Molecular Biomarkers of Normal Nasopharyngeal Tissue

Nasopharyngeal Carcinoma

China
Sun Yat-sen University
Wuzhou Red Cross Hospital; Hunan Cancer Hospital; Cancer Hospital of Guizhou... and other collaborators

Active, not recruiting

Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Sun Yat-sen University

Active, not recruiting

PD-1 Antibody Versus Best Supportive Care After Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma (DIPPER)

Nasopharyngeal Neoplasms

China
Akeso
Akeso Tiancheng, Inc

Completed

A Study of Penpulimab Combination Therapy in Patients With Advanced Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
University Health Network, Toronto

Active, not recruiting

Nasopharyngeal Carcinoma Post IMRT

Nasopharyngeal Carcinoma

Canada
Sue Yom
Bristol-Myers Squibb; National University Cancer Institute, Singapore

Active, not recruiting

Nivolumab + Chemoradiation in Stage II-IVB Nasopharyngeal Carcinoma (NPC)

Nasopharyngeal Carcinoma

United States, Singapore
Zhongshan People's Hospital, Guangdong, China

Active, not recruiting

Nasopharyngeal Carcinoma Screening in Zhongshan City

Nasopharyngeal Carcinoma

China
Sun Yat-sen University

Active, not recruiting

Phase Ⅲ Trial of Adjuvant Chemotherapy in Patients With N2-3 Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Chang Gung Memorial Hospital

Completed

PET and MRI in Prognosis Prediction of NPC

Nasopharyngeal Carcinoma

Taiwan
Sichuan Cancer Hospital and Research Institute
Jiangsu HengRui Medicine Co., Ltd.

Completed

Maintenance Therapy of Apatinib After Chemoradiotherapy in Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Neoplasms

China
Sun Yat-sen University
Innovent Biologics (Suzhou) Co. Ltd.

Active, not recruiting

Sintilimab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma (CONTINUUM)

Nasopharyngeal Neoplasms

China
Affiliated Cancer Hospital & Institute of Guangzhou...

Completed

Nedaplatin in Treatment for Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Fudan University

Completed

Anti-EGFR Therapy Plus IMRT Concurrent Chemoradiotherapy in Locally Advanced NPC Resistant to Induction Chemotherapy

Nasopharyngeal Carcinoma

China
First Affiliated Hospital of Guangxi Medical University

Completed

Endostar Combined With Intensity-modulated Radiotherapy Compare With Chemoradiation for Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Sun Yat-sen University

Active, not recruiting

Concurrent Chemoradiotherapy With Nimotuzumab for High Risk Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Massachusetts General Hospital
Dana-Farber Cancer Institute; Brigham and Women's Hospital

Completed

Proton Radiotherapy With Chemotherapy for Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

United States
Sun Yat-sen University

Withdrawn

Concurrent Chemotherapy in Intermediate Risk Patients Treated With Intensity-modulated Radiotherapy

Nasopharyngeal Carcinoma

China
Sun Yat-sen University

Active, not recruiting

Reduced-dose Radiotherapy for Low-risk Stage III Patients With Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Sun Yat-sen University
Guilin Medical University, China; First People's Hospital of Foshan

Unknown

Prospective Study for Prognostic Biomarkers of Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
The University of Hong Kong

Unknown

Serial Plasma EBV DNA for Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Hong Kong
Sun Yat-sen University

Unknown

Clinical Target Volume Based on Disease Extension Risk Atlas and Computer-aided Delineation in Nasopharyngeal Carcinoma

Nasopharyngeal Neoplasms

China
Chaosu Hu

Unknown

De-escalation Protocols in Locoregionally Advanced Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Sun Yat-sen University

Completed

Prospective Comparisons of Clinical Trial and Real-world Outcomes in Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Hong Kong Nasopharyngeal Cancer Study Group Limited
The Hong Kong Anti-Cancer Society; hong Kong Cancer Fund

Completed

Therapeutic Gain by Induction-concurrent Chemoradiotherapy and/or Accelerated Fractionation for Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
National University Hospital, Singapore

Completed

Study Evaluating Two Loading Regimens of Sunitinib or Bevacizumab Alternating With Cisplatin and Gemcitabine as Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma (NPC)

Nasopharyngeal Carcinoma

Singapore

Clinical Trials on Charcot-Marie-Tooth Disease Type 2L (Diagnosis)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritius

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations